Protagonist Therapeutics (PTGX) Downgraded by BidaskClub
Several other equities analysts have also recently weighed in on PTGX. Zacks Investment Research upgraded Protagonist Therapeutics from a sell rating to a hold rating in a report on Thursday, December 20th. ValuEngine cut Protagonist Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 2nd. Finally, BMO Capital Markets started coverage on Protagonist Therapeutics in a report on Friday, February 22nd. They issued an outperform rating and a $17.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Protagonist Therapeutics currently has an average rating of Buy and an average target price of $15.45.
PTGX opened at $10.66 on Friday. Protagonist Therapeutics has a 1 year low of $5.49 and a 1 year high of $14.36. The stock has a market capitalization of $259.42 million, a price-to-earnings ratio of -6.13 and a beta of 2.19.
In related news, CEO Dinesh V. Ph D. Patel sold 10,909 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total transaction of $84,435.66. Following the completion of the transaction, the chief executive officer now owns 367,396 shares in the company, valued at $2,843,645.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Y. Liu sold 3,821 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total value of $29,574.54. Following the transaction, the insider now owns 37,007 shares of the company’s stock, valued at approximately $286,434.18. The disclosure for this sale can be found here. Insiders have sold 17,570 shares of company stock valued at $136,815 in the last quarter. 13.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in shares of Protagonist Therapeutics by 250.8% during the third quarter. JPMorgan Chase & Co. now owns 240,638 shares of the company’s stock worth $2,476,000 after acquiring an additional 172,047 shares during the period. FMR LLC boosted its holdings in shares of Protagonist Therapeutics by 8.7% during the third quarter. FMR LLC now owns 3,457,402 shares of the company’s stock worth $35,577,000 after acquiring an additional 276,819 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Protagonist Therapeutics by 61.5% during the third quarter. Dimensional Fund Advisors LP now owns 368,017 shares of the company’s stock worth $3,787,000 after acquiring an additional 140,200 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Protagonist Therapeutics by 12.3% during the third quarter. Renaissance Technologies LLC now owns 537,200 shares of the company’s stock worth $5,528,000 after acquiring an additional 58,900 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Protagonist Therapeutics by 2.6% during the third quarter. Vanguard Group Inc. now owns 530,495 shares of the company’s stock worth $5,458,000 after acquiring an additional 13,341 shares during the period. Institutional investors and hedge funds own 59.37% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Further Reading: Hedge Funds – Risk or Reward?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.